The aim of this research study is to evaluate the effectiveness and safety of a combination of immunotherapy, using a drug called toripalimab, with chemotherapy drugs, Carboplatin and Docetaxel, as a possible treatment before surgery for sinonasal cancers.
The names of the study drugs used in this research study are:
* Toripalimab (a type of monoclonal antibody)
* Carboplatin (a type of antineoplastic agent)
* Docetaxel (a type of antineoplastic agent)
* Cisplatin (a type of antineoplastic agent)

开始日期2025-10-01

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+1]

NCT06682780

/ Not yet recruiting临床1/2期

An Open-label, Dose-escalation, and Dose-expansion Phase I/II Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Efficacy of LM-2417 for Injection Alone or in Combination With Other Antitumor Agents in Patients With Advanced Solid Tumors

This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours.

开始日期2025-06-05

申办/合作机构

礼新医药科技（上海）有限公司

NCT06987123

/ Not yet recruiting临床2期IIT

Toripalimab in Combination With Capecitabine as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial

Regarding the application value of capecitabine metronome chemotherapy's regulatory effect on the immune microenvironment in nasopharyngeal carcinoma, many studies in recent years have confirmed that metronome chemotherapy and immunotherapy are safe and effective in resectable recurrent nasopharyngeal carcinoma. Therefore, the investigators plan to conduct a "single-arm clinical study on adjuvant therapy of toripalimab combined with capecitabine after Surgery for locally recurrent resectable nasopharyngeal carcinoma" to explore the efficacy and safety of toripalimab combined with capecitabine as adjuvant therapy after salvage surgery for resectable recurrent nasopharyngeal carcinoma. If this study is confirmed, it is expected to provide a new treatment model for patients with resectable recurrent nasopharyngeal carcinoma.

开始日期2025-05-18

申办/合作机构

中山大学

100 项与特瑞普利单抗相关的临床结果

登录后查看更多信息

100 项与特瑞普利单抗相关的转化医学

登录后查看更多信息

100 项与特瑞普利单抗相关的专利（医药）

登录后查看更多信息

2,391

项与特瑞普利单抗相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis

Article

作者: Zhang, Lingli ; Xu, Kai ; Yu, Man ; Lin, Yingtao ; Li, Xin ; Su, Dan ; Shang, Jingjing ; Sun, Qingli ; Gong, Jinhong ; Qian, Xiaodan

BACKGROUND:

Programmed death-1 (PD-1) inhibitors combined with chemotherapy have become a standard first-line treatment for advanced oesophageal squamous cell carcinoma (ESCC). Given the high costs associated with immunotherapy, evaluating the cost-effectiveness of different PD-1 inhibitors in the Chinese healthcare setting is essential for guiding treatment decisions and policy development.

METHODS:

A cost-effectiveness analysis was conducted comparing six PD-1 inhibitors-sintilimab, toripalimab, tislelizumab, camrelizumab, serplulimab, and pembrolizumab-combined with chemotherapy for first-line treatment of advanced ESCC. A partitioned survival model was used to calculate incremental cost-effectiveness ratios (ICERs) from healthcare system perspective, with a willingness-to-pay (WTP) threshold set at $36,598.19 per quality-adjusted life year (QALY). Sensitivity analyses were performed to evaluate the robustness of the results.

RESULTS:

The ICERs for toripalimab, camrelizumab, pembrolizumab, serplulimab, sintilimab, and tislelizumab were $32,356.79/QALY, $48,410.64/QALY, $312,743.54/QALY, $121,200.84/QALY, $29,663.42/QALY, and $35,304.33/QALY, respectively. Sintilimab, toripalimab, and tislelizumab were below the WTP threshold. Among all regimens, the top three in life years (LYs) gained were toripalimab, serplulimab, and tislelizumab. Sensitivity analysis showed that utility values and drug prices were key factors influencing ICERs. Probabilistic analysis indicated that toripalimab, sintilimab, and tislelizumab had the highest probabilities of being cost-effective, at 83.1%, 81.4%, and 70.0%, respectively.

CONCLUSION:

Sintilimab, toripalimab, and tislelizumab are the most cost-effective PD-1 inhibitors when combined with chemotherapy for the first-line treatment of advanced ESCC in China, with ICERs below the WTP threshold. While all six PD-1 inhibitors demonstrated clinical benefits, pembrolizumab and serplulimab were less favourable from a cost-effectiveness standpoint. Sensitivity analysis confirmed that drug prices and utility values are significant determinants of cost-effectiveness.

2025-12-01·Journal of Gastrointestinal Cancer

90Y-Transarterial Radioembolization Combined with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A Systematic Review

Review

作者: Shobeiri, Parnian ; Lewandowski, Robert J ; Fowler, Kathryn J ; Behnoush, Amir Hossein ; Hosseini Shabanan, Sedighe ; Haghshomar, Maryam

BACKGROUND:

Transarterial radioembolization with yttrium-90 (⁹⁰Yt-TARE) and immune checkpoint inhibitors (ICIs) are emerging as treatment modalities for intermediate to advanced hepatocellular carcinoma (HCC) based on randomized controlled trials. Herein, we systematically reviewed the published literature on the effects of ⁹⁰Yt-TARE and ICIs combined on clinical outcomes of HCC.

METHODS:

Medical databases of PubMed, Embase, and Cochrane Library were systematically searched for all studies assessing the use of concomitant immunotherapy of ICI with TARE in patients with HCC. Patient characteristics, treatment protocols, treatment outcomes, treatment adverse events, and survival outcomes were extracted after the screening phase. The primary outcomes were overall survival (OS) and patient-free survival (PFS), while the secondary outcomes were imaging objective response (OR) and adverse events.

RESULTS:

Among 3432 reviewed, ten studies were included in this systematic review, including four randomized controlled trials and six retrospective studies. These consisted of 413 patients with HCC, and seven studies included patients with Child-Pugh A or B7 scores. Most studies allowed advanced or intermediate HCC stages, but only two specified BCLC stages (B and C). Median tumor sizes ranged from 56 to 78.5 mm. Various agents with different administration schedules were used as ICIs for immunotherapy by different studies for the combination of ⁹⁰Yt-TARE with ICIs. Median OS ranged from 16.2 to 27 months between different studies while the PFS also ranged from 5.6 to 13.3 months. The OR rates according to imaging-based response assessments were reported between 31 and 89%, and the incidence rate of any grade toxicities was between 50 and 80%.

CONCLUSION:

Concomitant treatment with ⁹⁰Yt-TARE and ICIs has shown promising results in the treatment of patients with HCC. Further studies are required to reach a consensus on the optimal treatment protocol and the outcome of these treatments for patients with intermediate to advanced HCC.

2025-06-01·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Efficacy and safety of targeted therapy and immunotherapy in advanced vulvar squamous cell carcinoma: A scoping review

Review

作者: Arenhardt, Martina Parenza ; de Andrade, Diocesio Alves Pinto ; Dos Santos, Marcela Bonalumi ; de Melo, Andréia Cristina ; Gomes, Larissa Müller ; da Silva, Jessé Lopes ; Giannecchini, Giovanna Vieira

INTRODUCTION:

Vulvar squamous cell carcinoma (VSCC) is a rare gynecological tumor with limited treatment options for advanced stages. Current chemotherapy, adapted from cervical cancer protocols, often results in poor outcomes. This scoping review evaluates the efficacy and safety of immunotherapy and targeted therapies in advanced VSCC.

MATERIAL AND METHODS:

After extensive assessment, examination, and curation of relevant literature data, eight trials focused on immunotherapy or targeted therapy for advanced, recurrent, or metastatic VSCCs were identified and selected. The findings have been compiled and synthesized into a narrative overview, adhering to the PRISMA-ScR guidelines.

RESULTS:

The study analyzed four unpublished and four published trials, evaluating the efficacy and safety of immunotherapy or targeted therapy for VSCCs. Pembrolizumab was assessed in the KEYNOTE-028 and KEYNOTE-158 trials, showing objective response rates (ORRs) of 6 % and 10.9 %, respectively, and median overall survival (OS) between 3.8 and 6.2 months. CheckMate 358 reported a 20 % ORR for nivolumab. Combination strategies (ipilimumab plus nivolumab and pembrolizumab plus vorinostat) demonstrated efficacy with median OS of 7.6 and 17.5 months, respectively. Toripalimab showed an ORR of 33.3 %. Safety profiles were generally manageable, with common adverse events like fatigue and gastrointestinal disorders. Serious adverse events included grade 5 immune-related hepatitis and chronic kidney disease.

CONCLUSION:

Immunotherapy may be considered an option for VSCCs in the second-line setting. Despite the limited research on targeted therapies for VSCCs, combination approaches with immunotherapy demonstrate promising potential. Prioritizing the identification of biomarkers that predict responses to immune checkpoint inhibitors is essential.

1,619

项与特瑞普利单抗相关的新闻（医药）

2025-05-26

·动脉网

AACR 2025年会全球肿瘤研发趋势全景分析：靶点格局、机构布局与AI技术融合

随着精准医疗与技术创新的不断演进，肿瘤药物研发正在经历深度重构。从靶点聚焦、疾病领域分布，到机构参与模式与技术路径，全球研究版图愈加清晰。特别是在2025年AACR年会公布的研究汇总分析后，核心趋势已逐渐呈现：传统靶点依旧强势，新兴靶标加速突破，机构分工更趋专业化，AI技术全面渗透药物发现与诊疗预测环节。本篇行业研究基于AACR 2025发布的全量摘要数据，系统梳理了全球肿瘤研发三大维度：（1）疾病与靶点研究热点，（2）机构类型与技术趋势，以及（3）AI在肿瘤研究中的融合应用。通过对7100余篇AACR 2025参会文章的内容归类与解析，本文旨在帮助读者快速掌握全球肿瘤研发的核心焦点、地区与机构间的差异化布局、前沿靶点的落地路径与AI技术赋能的实际场景。01全球肿瘤研究热点方向1.1 实体瘤为研究主战场，血液系统次之根据AACR 2025年会公布的研究统计数据，实体瘤研究占比高达89.14%，远超血液系统肿瘤（8.34%）及其他疾病类别（如代谢性疾病0.89%、免疫性疾病0.66%）[1]。这一研究格局与全球肿瘤负担相吻合。GLOBOCAN 2020报告显示，肺癌、乳腺癌和结直肠癌等固态瘤种占新发癌症病例的60%以上[2]，实体瘤仍是当前抗肿瘤药物开发和基础研究的核心领域。来源：根据AACR 2025大会网站信息，医药魔方的数据整理1.2 系统性肿瘤研究重心分布与临床负担吻合对实体瘤进一步分类发现，乳腺及妇科肿瘤（26.7%）与消化系统肿瘤（26.7%）并列为研究比例最高的领域，其次为呼吸系统肿瘤（16.1%）和泌尿生殖系统肿瘤（12.1%）[1]。这与全球高发癌种排名基本一致，其中乳腺癌为女性最常见肿瘤（占11.7%），结直肠癌和肺癌紧随其后[2]。在血液系统肿瘤中，白血病研究占比达52.8%，遥遥领先于淋巴瘤（27.4%）与浆细胞瘤（15.4%）。近年来，CAR-T、BiTE以及Bcl-2抑制剂等靶向策略的突破推动了白血病治疗手段的快速演进，呈现出细胞疗法与靶向药物双线并进的格局。感染相关疾病领域，HPV病毒致癌机制相关研究占据主导地位（46.2%），远超EBV相关研究（5.1%）。近年来研究焦点已由预防型HPV疫苗转向治疗性疫苗与免疫联合疗法开发，其在宫颈癌、头颈癌等肿瘤治疗中展现潜力。来源：根据AACR 2025大会网站信息，医药魔方的数据整理在代谢相关疾病中，研究集中于Ⅰ/Ⅱ型糖尿病（36.4%）与肥胖（30.3%）背景下的肿瘤易感性，其余如高胆固醇血症（15.2%）、胰岛素抵抗（6.1%）研究占比相对较小。流行病学研究证实，肥胖和Ⅱ型糖尿病显著增加胰腺癌和结直肠癌的发病风险[3]，提示代谢失衡是重要的肿瘤致病背景，亦为早筛与干预提供新方向。免疫相关疾病研究中，自身免疫病（41.3%）与炎症性肠病（IBD，23.9%）最受关注。IBD患者的结直肠癌风险是常人的2倍以上[4]，慢性炎症对肿瘤微环境的重塑作用正成为研究热点。该类研究有助于进一步解析免疫调控与肿瘤发生之间的关联。在遗传性癌症综合征研究中，林奇综合征（64.3%）为最主要研究对象，其在结直肠癌和子宫内膜癌中的早筛与风险管理已纳入临床指南。遗传性肿瘤研究强调对高危人群的早期干预与个体化防控策略。肿瘤相关并发症研究则聚焦于治疗相关毒性（71.4%），如细胞毒性、免疫不良反应等，远高于放射诱导性纤维化（28.6%）。随着治疗技术的升级，并发症管理日益成为优化临床方案不可忽视的部分。来源：根据AACR 2025大会网站信息，医药魔方的数据整理1.3 癌种亚型精细化研究趋势明显在乳腺及妇科肿瘤中，乳腺癌研究占比达59.3%，为最主要研究方向，卵巢癌（18.3%）与三阴性乳腺癌（TNBC，8.8%）紧随其后。三阴性乳腺癌因缺乏激素及HER2靶点，正积极探索T细胞引导疗法与抗体偶联药物（ADC）策略[5]。乳腺癌亚型研究逐步从分子分型向精准靶向与免疫联合推进。在消化系统肿瘤中，结直肠癌（38.4%）和胰腺癌（32.1%）为研究重点。胰腺癌因五年生存率低于10%，被广泛视为“难治性实体瘤”的攻坚方向；肝癌（13.3%）与胃癌（9%）研究关注亦不断升温。呼吸系统肿瘤以非小细胞肺癌（NSCLC，45.5%）、肺腺癌（13.1%）及小细胞肺癌（SCLC，12.2%）为主要研究对象，EGFR突变、ALK融合等经典靶点持续受到关注。来源：根据AACR 2025大会网站信息，医药魔方的数据整理泌尿生殖系统肿瘤中，前列腺癌（62.4%）研究占比最高，肾癌（15.1%）、膀胱癌（13.9%）次之。PSMA靶向放射性治疗与AR螺旋酶抑制剂相关成果获得FDA优先审评资格[6]，AR与PSMA双靶点策略成为前列腺癌治疗焦点。此外，肉瘤、神经系统与头颈部肿瘤的研究各有聚焦，主要关注稀有靶点、特定分子变异及免疫相关机制。血液系统肿瘤依然以白血病（49.6%）与淋巴瘤（25.3%）为主，罕见亚型研究正在获得更多关注，推动治疗手段与生物标志物的进一步多样化与精准化。来源：根据AACR 2025大会网站信息，医药魔方的数据整理1.4 TOP10 靶点研究：“广谱核心+系统特异”并进消化系统肿瘤靶点覆盖传统驱动基因（KRAS、EGFR、TP53）、免疫通路（PD-1/PD-L1）及关键信号通路（PI3K/AKT、β-catenin），展现“靶向+免疫+信号通路联合”的发展趋势。KRAS为胰腺导管癌和结直肠癌的核心驱动基因，G12C抑制剂sotorasib联合panitumumab方案已获FDA批准用于KRAS G12C突变的转移性结直肠癌[7]。TP53为最常突变的抑癌基因，突变率在消化系统肿瘤中显著偏高[8]。PD-1/PD-L1抑制剂在MSI-H/dMMR型结直肠癌中作为一线治疗已被证实有效，KEYNOTE-177试验中pembrolizumab改善了生存期与耐受性[9]。肺癌聚焦EGFR和KRAS等传统靶点，同时引入免疫策略及新靶点DLL3。第三代EGFR TKI（如lazertinib）联合抗体amivantamab已获批，开启“TKI+抗体”治疗时代[10]。KRAS G12C抑制剂在NSCLC中率先获批，并拓展至其他亚型。DLL3为小细胞肺癌特异性靶点，双特异抗体和CAR-T疗法正在临床早期阶段展现潜力。来源：根据AACR 2025大会网站信息，医药魔方的数据整理泌尿生殖系统肿瘤以AR和PSMA为前列腺癌核心靶点，同时扩展至PD-L1和Nectin-4。Pluvicto®（PSMA靶向放射配体）已被批准用于mCRPC[11]。膀胱癌中Nectin-4靶向ADC（如enfortumab vedotin）临床获益显著。乳腺与妇科肿瘤采用“信号通路+DNA修复+免疫”组合策略，HER2（23.9%）与ER（13.2%）为两大核心靶点。来源：根据AACR 2025大会网站信息，医药魔方的数据整理罕见实体瘤聚焦免疫检查点与融合蛋白，尤文氏肉瘤的EWS-FLI1已成为关键候选靶点。PD-1（24.7%）、p53（12%）、CTLA-4（10.1%）等位居研究前列。BRAF在黑色素瘤中应用广泛，PD-1与CTLA-4联合治疗已成为标准方案。神经系统肿瘤主要靶向EGFR、p53、MGMT及IDH1，构建精准治疗组合。头颈部肿瘤则结合免疫靶点与病毒抗原，探索表观遗传路径。血液系统则聚焦Bcl-2调控、CD19/BCMA CAR-T与双抗，以及BTK/FLT3信号通路。来源：根据AACR 2025大会网站信息，医药魔方的数据整理综上，p53与PD-1/PD-L1在六大系统中均位列TOP10，显示广泛的治疗适用性。KRAS与EGFR在消化与呼吸系统中均为核心靶点，反映其在实体瘤中的共性机制。同时，各系统也呈现独特靶点：AR/PSMA限于前列腺癌，EWS-FLI1专属尤文氏肉瘤，MGMT/IDH1聚焦神经系统，CD19/BCMA聚焦血液肿瘤，HPV抗原集中于头颈部肿瘤，明确揭示了肿瘤靶向治疗的“共性+特异”结构。1.5 见解：TOP3 系统肿瘤靶点分布与技术趋势消化系统肿瘤（胃肠、肝胆胰等）：代表性靶点包括EGFR、HER2、KRAS、BRAF、PI3K、VEGF等传统靶点；新兴靶点如Claudin18.2（柯德素2）和GPC3在胃癌、肝癌中受关注[1]。例如，Claudin18.2抗体zolbetuximab已获批用于胃食管腺癌[12]，对应研究也在AACR等会议频繁报道。KRAS突变（尤其G12C/G12D）在胰腺癌和结直肠癌中高发，目前针对KRAS G12C的抑制剂已上市，而新型G12D抑制剂（如zoldonrasib、MRTX1133）正显示出临床前和I期疗效[13,14]。免疫检查点（如PD-1/PD-L1）和新型ADC靶点（如HER2、TROP2）也占据主要研究阵地。总体来看，消化道肿瘤靶向研发既延续了对EGFR、HER2、KRAS等传统靶点的关注，同时积极拓展Claudin18.2、GPC3、FGFR2（胆管癌）等新靶点的潜力。呼吸系统肿瘤（主要指肺癌）：关键靶点包括EGFR、ALK、ROS1、BRAF、MET、RET、KRAS以及免疫靶点PD-1/PD-L1等传统目标；同时出现诸如HER2突变、NRG1融合（HER3相关）、TIGIT、DLL3等新靶点。典型案例是肺癌：第3代EGFR抑制剂（如lazertinib）已与双特异抗体amivantamab联合获FDA批准[15]；KRAS G12D抑制剂zoldonrasib呈现初步临床活性[16]；HER3靶向双特异抗体zenocutuzumab（针对NRG1融合肿瘤）实现了临床突破[17]。新药开发方面，研究重点正从传统EGFR/ALK等靶点拓展到KRAS变体、HER2/HER3信号通路以及各种免疫通路的联合抑制。可见，肺癌领域的靶点分布呈现“老靶点加新靶点并行”的趋势。泌尿生殖系统肿瘤（前列腺、膀胱、肾脏等）：前列腺癌以雄激素受体（AR）为传统靶点，近期PSMA（前列腺特异膜抗原）放射性核素治疗获得FDA批准（Pluvicto™）[18]，展示了新靶点带来的治疗潜力。膀胱癌研究中，FGFR3突变/融合常见，对应靶向药如pemigatinib获批；Ras/MAPK和PD-1免疫靶点也在临床试验中占据重要地位。肾癌则以VEGF/VEGFR（抗血管生成）和mTOR路径为经典靶点，近年来对免疫检查点和新型靶点如HIF-2α抑制剂（belzutifan）等展开布局。总的来看，泌尿生殖系统肿瘤中，传统靶点仍主导（如AR、VEGFR、FGFR），但新靶点（PSMA、HIF-2α、各种免疫检查点）研究热度显著上升。1.6 见解：传统 vs 新兴靶点：研发热度与创新潜力传统靶点（KRAS、EGFR、p53等）：这些靶点历经多年研究，目前在研发中仍占据主导地位。KRAS家族是典型代表，近年来G12C抑制剂（sotorasib、adagrasib）成功上市，研究重心逐渐向G12D等其他变体转移。例如，zoldonrasib作为首个口服KRAS G12D抑制剂，在KRAS G12D突变的NSCLC患者中取得了客观缓解[16]；MRTX1133在胰腺癌模型中诱导深度肿瘤退缩[14]。EGFR靶向仍是肺癌研究热点，新一代EGFR抑制剂联用双特异抗体方案已进入临床并获批[15]。p53作为经典肿瘤抑癌基因，其直接靶向仍具挑战性，当前更多研究集中在p53基因补偿疗法或相关通路（如MDM2）的干预。在药企布局方面，大型制药公司持续推进这些经典靶点的升级药物和组合疗法，例如多靶点抑制剂和新型抗体偶联药物等。新兴靶点（BCMA、PSMA、CD19等）：这些靶点在近年研究中活跃度显著上升，创新潜力巨大。以血液肿瘤为例，BCMA靶向治疗（CAR-T和双特异抗体）已成为多发性骨髓瘤治疗的焦点。Roche/Poseida开发的全新异体CAR-T产品P‑BCMA‑ALLO1在复发/难治MM患者中展示了91%总缓解率[19]，显示出比单靶向更强的疗效。PSMA靶向策略在前列腺癌表现亮眼，^177Lu-PSMA放射性核素治疗（Pluvicto）已获准用于晚期转移性前列腺癌并正在拓展至一线应用[18]。B淋巴瘤靶点CD19则通过CAR-T和双靶CAR-T等新技术持续创新，合作开发的双抗CD19/CD20 CAR-T首次实现异体双靶CAR-T临床应用[19]。这些新靶点的研究通常伴随着新型疗法平台（如CAR-T、双抗体、ADC、多特异抑制剂）同步推进，使其在AACR等会议上成为讨论热点。此外，ADC、肿瘤疫苗、CRISPR免疫治疗等技术趋势正在为传统和新靶点研究注入新动力，激发更多创新。1.7 见解：TOP10研究机构画像AACR 2025中排名前列的机构主要包括MD安德森癌症中心、Memorial Sloan Kettering（MSKCC）、Dana-Farber癌症研究所、约翰霍普金斯大学、NCI/NIH等。这些中心往往拥有多学科整合的平台和丰富的临床资源。例如，MSKCC领导的免疫疗法研究组在错配修复缺陷（MMRd）实体瘤中报道了PD-1抗体dostarlimab的新辅助疗法，80%患者完成治疗后无需手术[20]；其团队还获得AACR奖项以表彰MSK-IMPACT基因测序平台的贡献[21]。MD安德森则在PARP抑制剂联合免疫疗法、数字孪生模型等领域持续发力，本次报告了针对BRCA突变患者的PARP+PD-1组合试验早期数据[20]。Dana-Farber在头颈癌、肺癌和乳腺癌等多种疾病中保持领先地位，重点研究方向包括HPV阴性头颈癌的新辅助免疫治疗、KRAS突变肺癌联合通路抑制[22]以及乳腺癌抗耐药联合方案等。以上机构的共同优势在于强大的科研实力、多中心临床试验网络以及跨学科合作（如免疫学、基因组学与临床研究结合），使其在AACR发文中表现突出。来源：根据AACR 2025大会网站信息，医药魔方的数据整理02研发机构类型、地区与创新分布2.1 机构类型与地区：大学领跑，北美为重心在AACR 2025大会披露的研究数据中，高校机构占据主导地位，占比达35.6%，凸显其在基础研究与创新路径探索中的重要作用。企业和医院分别占据22.9%和22.5%，体现出产业转化和临床验证作为肿瘤研发核心驱动的双轮结构。独立研究机构占比16.3%，展现其在方法学、平台开发与基础生物学中的支撑性角色。从地区分布来看，北美以57.5%的占比稳居全球肿瘤研究高地，其中美国的研究机构公布研究数量超过4700多份，远超全球其他国家，稳居全球第一；亚洲（21.9%）与欧洲（17.5%）紧随其后，中国以758的公布数量占据全球第二，其后是韩国388；英国、法国、德国、西班牙和意大利均位列全球前十，是欧洲癌症研究关注度和投入较高的区域，与当地的人口体量具有较强的相关性。相较之下，大洋洲（1.3%）、南美（1.0%）及非洲（0.9%）占比较低，提示肿瘤研究在全球尚有地域拓展与合作潜力。来源：根据AACR 2025大会网站信息，医药魔方的数据整理2.2 药物品种研发趋势：抗体与小分子双核驱动，新体系加速拓展大学、企业、医院与独立研究机构在肿瘤药物研发路径上呈现“双核（小分子+大分子）主导、平台技术融合”的共性框架，并在具体布局上各具特点。高校倾向于以小分子为主（占比约40%），其中约30%集中在TKI与传统靶向药，另有25%左右聚焦于ADC、双抗、PROTAC与AI辅助筛选等前沿平台，体现其基础研究与技术验证双向优势。企业则呈现出“30%小分子+20%抗体+20%ADC+10%免疫检查点”四足并进结构，同时在靶向蛋白降解与放射性配体等新兴机制（10%）方面快速推进商业化。医院机构更聚焦临床应用，抗体药物（25%）与免疫调节剂（15%）布局靠前，搭配小分子（30%）与细胞/基因疗法（10%），体现其对一线治疗与CAR-T平台的双重重视。研究机构中，“其他”创新平台（占比约35%）居首，其次为小分子（30%）和ADC（15%），更偏重高通量靶点筛选与机制创新。整体来看，四类机构在稳固传统路径的同时，正加速布局多模态、跨平台的新兴疗法，显示肿瘤药物研发正向“靶点+平台”双驱动战略演进。来源：根据AACR 2025大会网站信息，医药魔方的数据整理2.3 各类机构聚焦的TOP10靶点分析在靶点选择上，PD1、PDL1、EGFR、HER2、KRAS与p53为各类机构共同关注的核心靶点，反映免疫检查点与驱动突变位点在肿瘤治疗中的长期战略地位。大学倾向于围绕MYC、AR、Akt、PI3K等基础生物学靶点进行探索，突出其在信号转导、细胞周期和内分泌肿瘤机制研究中的学术深度。企业则集中于CD3、TROP2、CTLA-4等免疫靶点，布局双抗、CAR-T、ADC等商业潜力明确的新兴治疗形式。医院更关注CDKN2A等与患者分型和临床转化密切相关的靶点，体现其桥接基础与临床的优势。研究机构则重点发力Ras、Akt等信号通路关键节点，强化对肿瘤依赖机制的机制性解析与早期验证。来源：根据AACR 2025大会网站信息，医药魔方的数据整理2.4 全球TOP20 MNC的研发趋势全球TOP 20跨国药企（MNC）在药物类型方面，小分子药物仍为主导（33%），但大分子（19.7%）及技术驱动类药物（7.1%）比例持续上升，体现出研发模式由传统单一平台向多技术耦合的方向演进。在疾病布局上，消化系统肿瘤、乳腺及妇科肿瘤、呼吸系统肿瘤为三大重点领域，分别占18%、18%和16.6%，对应全球肿瘤负担高发趋势。在靶点选择上，PD1、EGFR、PDL1、HER2的高频布局（分别为22、19、18和14次）验证其在免疫+靶向双线战术中的核心地位。表：全球TOP20 MNC公司名单来源：根据美国《制药经理人》公布信息整理来源：根据AACR 2025大会网站信息，医药魔方的数据整理在代表性药物方面，罗氏的选择性ER降解剂 giredestrant（用于HR+/HER2–乳腺癌）进入III期；阿斯利康的HER2-ADC Enhertu、Imfinzi在乳腺和肺癌中不断拓展适应症；诺华的放射性配体疗法Pluvicto（靶向PSMA）在前列腺癌中改善疗效并已上市[23]。此外，强生的EGFR/MET双抗Rybrevant联合方案和辉瑞的BRAF抑制剂Braftovi也体现出靶点协同策略的临床价值。在新兴技术平台方面，Arvinas的BCL6靶向PROTAC（ARV-393）进入I期临床，BMS的AR降解剂CC-199正在临床前推进[24-27]；CRISPR基因编辑疗法Casgevy（由Vertex与CRISPR Therapeutics联合开发）2023年在英国获批上市，成为首个CRISPR肿瘤疗法产品，代表靶点治疗正迈入基因级干预新阶段[28]。此外，多家药企在CAR-T、ADC以及靶向蛋白降解平台上的联合探索，正重塑下一代肿瘤治疗范式。2.5 中国TOP20药企的研发趋势中国头部药企近年来快速崛起，展现出“生物制品主导+新兴技术突破”的研发格局。统计显示，其在药物类型上对大分子药物（抗体、融合蛋白等）投入占比高达65%，形成对单抗、双抗、ADC等产品形态的研发优势；靶向蛋白降解类药物比例达15%，显示出在新机制药物方面的积极布局，尤其是在PROTAC和分子胶方向开始具备一定储备。在适应症选择上，消化系统肿瘤、乳腺及妇科肿瘤、呼吸系统肿瘤并列为重点关注方向，均占比24.1%，贴合国内肿瘤发病谱的高发趋势。在靶点层面，EGFR和PD-L1分别被提及4次和2次，反映出对经典靶点的持续关注。表：TOP20 中国制药公司名单来源：根据搜狐医药, 美国《制药经理人》，上市公司财报信息整理来源：根据AACR 2025大会网站信息，医药魔方的数据整理近年来，中国药企不断提升原始创新能力。以恒瑞医药为例，其HER2-ADC SHR-A1811已被纳入国家突破性治疗品种名单，并拥有10余个差异化ADC项目处于临床阶段[29]。华东医药则聚焦胃肠道肿瘤抗原，如CDH17/CLDN18.2双靶点ADC VBC108展现出双通路协同激活潜力[30]。在免疫治疗方面，国产首个PD-1/CTLA-4双抗“卡度尼利单抗”已上市，标志国产免疫联合策略进入成熟应用阶段[31]。PD-1单抗方面，君实生物、信达生物等头部企业已构建稳定管线；此外，融合蛋白（如艾加莫德α）和CAR-T/ADC项目也在“国产替代”逻辑下快速推进[32]。根据医药魔方数据统计，2016–2023年间，中国TOP20药企累计获批新药88款，其中64%聚焦肿瘤，41%为自主研发，59%通过引进与合作完成[33]。这表明在满足国内市场需求的同时，中国药企正通过国际合作与平台搭建，向更高水平的原始创新迈进。2.6 TOP20 国际科研机构的研究趋势全球领先科研机构展现出药物研发平台化、多样化的策略特征。在药物类型方面，小分子与大分子药物分别占比30.7%和10.8%，技术驱动类（如蛋白质降解、递送系统）占比7.2%，免疫调节剂与细胞/基因疗法分别为6.6%和6.2%，形成以靶点机制研究为核心、以平台融合为方向的多模态布局。在疾病关注上，消化系统肿瘤（22.2%）、乳腺及妇科肿瘤（19.7%）与呼吸系统肿瘤（12.1%）位列前三，反映出科研机构在贴合流行病学趋势的基础上，优先布局高发高致死性瘤种。在靶点层面，PD1与p53并列为最常被研究靶点（均被提及46次），凸显其在免疫微环境与基因稳定性机制研究中的基础性地位。表：全球TOP20 科研机构来源：根据《新闻周刊》和Statista公司公布的全球权威肿瘤治疗机构的信息整理来源：根据AACR 2025大会网站信息，医药魔方的数据整理2.7 TOP20 中国科研机构的研究趋势中国顶尖科研机构在肿瘤药物研究中同样呈现出平台多元、机制深化的趋势。在药物类型上，小分子仍占主导地位（28.5%），大分子（16.3%）与细胞/基因疗法（6.5%）占比逐年增长，反映出对前沿治疗手段的快速采纳。在疾病布局上，消化系统肿瘤（21.7%）、乳腺及妇科肿瘤（19.7%）和呼吸系统肿瘤（12.8%）依然是主力方向，研究聚焦与国际趋势保持一致。在靶点选择方面，PD-L1与EGFR并列第一（均被提及10次），显示出对免疫检查点和经典驱动基因的持续兴趣与深入研究。表：中国TOP20 科研机构来源：复旦大学医院管理研究所发布的《2023年度中国医院排行榜》和《2024年度中国卫生健康统计年鉴》的信息整理来源：根据AACR 2025大会网站信息，医药魔方的数据整理见解：国际与中国头部科研机构靶点研究趋势分析国际科研机构广泛应用CRISPR筛选、多组学集成与人工智能辅助识别，推动新靶点发现体系化发展。英国Wellcome Sanger研究所联合EMBL-EBI发起的“癌症依赖性图谱”项目，通过对20,000基因进行CRISPR敲除筛选，在300余个癌症模型中建立靶点优先级评分体系[34]。NCI主导的CPTAC项目通过蛋白质组+转录组一体化分析，已发现超2800个潜在可成药靶点[35]。AI也被广泛用于分子网络建模与靶点预测，在精准治疗策略中发挥基础作用[36]。这类成果多以开放数据共享形式发布，并通过Open Targets等联盟促进产业界转化。中国科研机构亦快速引入上述工具体系，部分团队已系统性开展CRISPR筛选、单细胞转录组测序与AI辅助药靶预测工作[37]。政策层面，《国家重大新药创制专项》推动“临床-实验室-企业”三位一体协同攻关，CPTAC数据库等国际资源也逐步向国内开放，助力靶点资源共享与本地化挖掘。2.8 共性与差异：全球与中国研发布局比较共性方面，全球与中国科研机构在靶点聚焦和平台技术上方向趋同，广泛研究PD-1/PD-L1、EGFR、HER2等核心靶点，并采用ADC、双抗、细胞治疗等多种形式落地药物创新；均积极引入蛋白质组学、AI算法与CRISPR筛选等技术手段，推进基础研究向药物开发的高效转化。差异方面，国际头部科研机构与药企依托全球资源，更早布局如KRAS、BCL6、SMARCA2/4等高壁垒靶点，并向PROTAC与CRISPR疗法等未来技术延伸。中国机构起步聚焦“国产替代”路径，以PD-(L)1等成熟靶点切入，近年转向CDH17、GPC3等差异化抗原及AI靶点筛选探索，形成“国产可及+局部突破”的组合策略。此外，跨国企业推动全球同步开发，而中国团队则以本地市场为核心，逐步对接国际标准与临床试验网络[38]。总体而言，中外研发体系在靶点布局和技术采纳上日趋融合，但在策略上各有侧重：国际机构重体系化与广度，中国团队则以速度与灵活机制加速差异化创新，构建“追赶+突围”的双路径体系。03AI赋能肿瘤研究的全球格局3.1 地区与机构画像在AACR 2025大会展示的研究中，人工智能（AI）已成为推动肿瘤学精准化发展的重要技术引擎。总体来看，美国在AI肿瘤研究中保持绝对领先地位，共计发布113篇相关摘要，占全球总量超过一半，延续了其在传统靶点开发与机构产出中的主导态势[39]。韩国（23篇）与英国（15篇）分列第二与第三，体现出亚洲和欧洲国家在AI医疗技术方面的政策支持和研发投入日益加强。中国以11篇排名第四，相较其在传统肿瘤研究中占据的区域份额（亚洲21.9%），在AI领域仍有广阔提升空间。机构方面，美国国立癌症研究院（NCI, 8篇）和芝加哥大学（7篇）为AI肿瘤研究产出最多的机构，其在传统免疫靶点研究中的高活跃度亦有所延续。MD Anderson癌症中心和三星医疗中心则体现出临床型机构在数据驱动医学中的多模态融合能力：前者建立肿瘤学数据科学研究所（IDSO），开发基于深度学习的HER2自动评分系统和肺癌预后AI模型[40]，后者则联合KAIST构建AI数字病理平台，并推进多模态影像学研究，覆盖呼吸、消化系统等核心疾病领域[41]。这些机构的共同特点是拥有高度结构化的医疗数据和多学科协作机制，为AI模型的临床转化提供坚实基础。来源：根据AACR 2025大会网站信息，医药魔方的数据整理表：头部机构近3年内AI研发布局案例来源：根据AACR 2025大会网站信息，National Cancer Institute, Pubmed和机构网站信息整理注：上表引用[1]Sinha, Sanju et al. “PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors.” Nature cancer vol. 5,6 (2024): 938-952.[2] Krishnamurthy, Savitri et al. “Fully Automated Artificial Intelligence Solution for Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Scoring in Breast Cancer: A Multireader Study.” JCO precision oncology vol. 8 (2024): e2400353.[3] Pan, Xiaoxi et al. “The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma.” Nature cancer vol. 5,2 (2024): 347-363.[4] Dolezal, James M et al. “Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology.” Nature communications vol. 13,1 6572. 2 Nov. 2022.[5] https://medicine-uchicago-edu.libproxy1.nus.edu.sg/new-i3lung-project-to-fund-ai-tools-for-improving-treatment-and-outcomes-for-lung-cancer-patients/[6]https://keai-kaist-ac-kr.libproxy1.nus.edu.sg/projects/smc-digital-pathology-consortium/[7] https://www.itnonline.com/content/samsung-receives-fda-clearance-ai-algorithms-detect-lung-nodules-chest-x-rays[8]https://www.cancer.gov/news-events/press-releases/2024/ai-tool-matches-cancer-drugs-to-patient3.2 疾病领域聚焦疾病研究方面，AI应用聚焦于高发癌种：呼吸系统肿瘤居首（25.8%），与传统研究中NSCLC的高热度（16.1%）相契合；消化系统肿瘤（21.5%）与结直肠癌、胰腺癌等高突变负荷肿瘤关联紧密；乳腺及妇科肿瘤（13.5%）虽略低于传统研究占比（26.8%），但已有HER2表达评分等AI辅助系统临床落地，表明该领域AI应用仍处于加速渗透期。来源：根据AACR 2025大会网站信息，医药魔方的数据整理3.3 AI研究靶点特征靶点层面，AI研究对EGFR与PD‑L1的关注度最高（均15.4%），与第二、第三部分中统计的传统研究热点高度吻合，显示AI工具正用于增强这些经典靶点的表型识别与疗效预测能力。AI在HER2与KRAS（各12.8%）的应用中亦表现活跃，特别是在肺癌和结直肠癌中，深度学习模型被用于非侵入性预测基因突变状态[40,42]。此外，免疫相关靶点如CD3（10.3%）、MHC‑I（7.7%）的显著上升，标志着AI在肿瘤免疫微环境建模与抗原呈递机制探索中的扩展能力。少见靶点如DLL3（5.1%）的出现，提示AI正被用于罕见靶标的发现与亚群识别，支持新兴疗法如BiTE或CAR-T的早期开发[43]。表：TOP10靶点的AI研发案例来源：根据AACR 2025大会网站信息，PMC和 Pubmed文献库信息整理注：上表引用[1]Nguyen, Hung Song et al. “Predicting EGFR Mutation Status in Non-Small Cell Lung Cancer Using Artificial Intelligence: A Systematic Review and Meta-Analysis.” Academic radiology vol. 31,2 (2024): 660-683.[2] Yan, Fang et al. “Artificial intelligence-based assessment of PD-L1 expression in diffuse large B cell lymphoma.” NPJ precision oncology vol. 8,1 76. 27 Mar. 2024.[3] Dong, Yunyun et al. “Multi-channel multi-task deep learning for predicting EGFR and KRAS mutations of non-small cell lung cancer on CT images.” Quantitative imaging in medicine and surgery vol. 11,6 (2021): 2354-2375.[4] Krishnamurthy, Savitri et al. “Fully Automated Artificial Intelligence Solution for Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Scoring in Breast Cancer: A Multireader Study.” JCO precision oncology vol. 8 (2024): e2400353.[5] Diao, James A et al. “Human-interpretable image features derived from densely mapped cancer pathology slides predict diverse molecular phenotypes.” Nature communications vol. 12,1 1613. 12 Mar. 2021.[6] Shao, Xiaoshan M et al. “High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets.” Cancer immunology research vol. 8,3 (2020): 396-408.[7] Frascarelli, Chiara et al. “Deep learning algorithm on H&E whole slide images to characterize TP53 alterations frequency and spatial distribution in breast cancer.” Computational and structural biotechnology journal vol. 23 4252-4259. 26 Nov. 2024.综上所述，AI在AACR 2025肿瘤研究中的布局已深入至主流机构、核心靶点与高发癌种的多个层面。当前的AI模型主要整合多组学数据、病理影像与临床信息，以实现复杂生物特征和分子表型的定量评估，对疾病特征进行分层预测，同时推动多模态数据交叉学习与智能协同。相较传统方法，AI赋能正使肿瘤的疗法和药物研发向“精准靶点发现+临床智能匹配”的方向升级，其在肿瘤的早期预测、患者筛选和精准治疗等环节的渗透将重塑未来肿瘤临床研究和药物开发模式。综上，全球肿瘤药物研发已步入“靶点+平台+智能”的三轴驱动时代。从实体瘤主导的靶点格局，到跨国药企与科研机构在新技术平台上的差异化尝试；从中国药企的国产替代到逐步崛起的创新靶点突破，再到AI技术对经典与新兴靶点的赋能重塑，2025年肿瘤研究生态已呈现出系统性变革特征。未来，靶点的“泛系统性”与“系统特异性”将共构临床策略主线；机构协作将加速从基础研究到转化应用的闭环效率；AI与多组学融合将成为肿瘤研究不可或缺的计算引擎。本研究报告希望为业界提供一份扎实的数据分析与趋势解读，助力各类主体在靶点选择、技术规划与国际协同中的前瞻决策与战略落位。张鸿宇浙江大学生物与医药工程在读博士中山大学管理学硕士法国格勒诺布尔高等经管学院金融硕士（公派留学）个人简介浙江大学生物医药工程在读博士，专攻AI辅助精准肿瘤筛查，药物设计与开发；曾就职于平安集团、恒健金控和广发证券体系，从事生物科技和医疗卫生机构一级股债投融资业务，拥有AI、精准医疗与金融交叉复合背景，兼具前沿医学研发与资本运作双重视角，专注于AI赋能的精准医疗及新药研发，注重成果转化和市场应用。（微信号：18927501292）引用[1] https://www-aacr-org.libproxy1.nus.edu.sg/meeting/aacr-annual-meeting-2025/aacr-fast-facts/[2] Sung H, Ferlay J, Siegel RL, et al. “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.” CA: A Cancer Journal for Clinicians, 71(3):209–249, 2021.[3] Lauby-Secretan B, Scoccianti C, Loomis D, et al. “Body Fatness and Cancer — Viewpoint of the IARC Working Group.” New England Journal of Medicine, 375(8):794–798, 2016.[4] Jess T, Rungoe C, Peyrin-Biroulet L. “Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-based Cohort Studies.” Gastroenterology, 143(4): 860–868.e4, 2012.[5] Bardia A, Tolaney SM, Loirat D, et al. “Sacituzumab Govitecan–Hziy in Metastatic Triple-Negative Breast Cancer.” New England Journal of Medicine, 384(16):1529–1541, 2021.[6] https://www.fda.gov/news-events[7] U.S. Food and Drug Administration. “FDA Approves Sotorasib in Combination With Panitumumab for KRAS G12C–Mutated Metastatic Colorectal Cancer.” FDA News Release, May 2024. [8] Kandoth C, McLellan MD, Vandin F, et al. “Mutational Landscape and Significance Across 12 Major Cancer Types.” Nature, 502(7471):333–339, 2013.[9] Andre T, Shiu KK, Kim TW, et al. “Pembrolizumab versus Chemotherapy for MSI‑High/Mismatch Repair‑Deficient Metastatic Colorectal Cancer (KEYNOTE-177): Final Analysis of a Randomised, Open‑Label, Phase 3 Study.” Lancet Oncology, 22(7):931–942, 2021.[10] U.S. Food and Drug Administration. “FDA Approves Amivantamab and Lazertinib Combination for EGFR Mutated NSCLC.” FDA News Release, June 2024. [11] U.S. Food and Drug Administration. “FDA Grants Regular Approval to Pluvicto® for PSMA‑Positive Metastatic Castration‑Resistant Prostate Cancer.” FDA News Release, March 2024. [12] Onclive. “FDA Approves Zolbetuximab Plus Chemo for CLDN18.2+ Gastric or GEJ Adenocarcinoma.” Jul 2024.[13] U.S. FDA. “FDA Approves Sotorasib in Combination With Panitumumab for KRAS G12C–Mutated Metastatic Colorectal Cancer.” May 2024.[14] AACR. “Abstract CT019: Zoldonrasib May Elicit Objective Responses in KRAS G12D-Mutated NSCLC.” AACR Annual Meeting 2025.[15] U.S. FDA. “FDA Approves Amivantamab and Lazertinib Combination for EGFR Mutated NSCLC.” Jun 2024.[16] Arbour KC，Tawee T，Yaeger R，et al.CT019-Preliminary safety and antitumor activity of zoldonrasib(RMC-9805)，an oral，RAS(ON)G12D-selective，tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer(NSCLC)from a phase 1 study in advanced solid tumors.Presented at:2025 AACR Annual Meeting;April 25-30,2025.[17] Schram, Alison M et al. “Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.” Cancer discovery vol. 12,5 (2022): 1233-1247. [18] U.S. FDA. “FDA Grants Regular Approval to Pluvicto® for PSMA‑Positive Metastatic Castration‑Resistant Prostate Cancer.” Mar 2024.[19]https://www.globenewswire.com/news-release/2024/11/26/2987189/0/en/Roche-enters-into-a-definitive-agreement-to-acquire-Poseida-Therapeutics-including-cell-therapy-candidates-and-related-platform-technologies.html.[20] Cercek A. et al. “PD-1 Blockade in Mismatch Repair–Deficient Locally Advanced Rectal Cancer.” NEJM 386(25):2434–2442, 2022.[21] https://www.aacrmeetingnews.org/news/aacr-to-recognize-2025-scientific-achievement-award-recipients-during-annual-meeting.[22] ASCO. “Abstract 123: KRAS-Mutant NSCLC: Dual Pathway Inhibition Plus Immunotherapy.” ASCO 2023 Annual Meeting.[23] Novartis. “Novartis’ Pluvicto receives FDA approval for PSMA-positive mCRPC.” Novartis Press Release, March 2024.[24] Johnson & Johnson. “Rybrevant™ (amivantamab) plus Lazertinib receives FDA approval.” J&J Press Release, June 2024.[25] Pfizer. “FDA approves Braftovi (encorafenib) for BRAF V600E-mutant metastatic colorectal cancer.” Pfizer News, April 2024.[26] Arvinas. “Arvinas reports first patient dosed in Phase 1 trial of ARV-393 PROTAC.” Arvinas Press Release, February 2024.[27] Bristol Myers Squibb. “BMS advances CC‑199, an AR degrader, into preclinical development.” BMS News, January 2024.[28] Vertex Pharmaceuticals. “Vertex and CRISPR Therapeutics announce FDA approval of Casgevy, first CRISPR therapy.” Vertex Press Release, December 2023.[29] Hengrui Medicine. “Hengrui’s novel HER2-ADC SHR-A1811 designated as Breakthrough Therapy by NMPA.” Hengrui Annual Report 2023.[30] CStone Pharmaceuticals. “Preclinical proof-of-concept data for VBC108 dual-target ADC presented at AACR 2025.” CStone News, April 2025.[31] Junshi Biosciences. “Junshi’s toripalimab achieves NDA acceptance for NSCLC in China.” Junshi News, February 2024.[32] Innovent Biologics. “Innovent’s Cadonilimab (AK104) approved by NMPA for relapsed/refractory cervical cancer.” Innovent Press Release, May 2024.[33] Pharmcube (医药魔方). “2023 China Top20 Pharma R&D Landscape Report.” Pharmcube, January 2024.[34] Schumacher TN, Schreiber RD. “Neoantigens in cancer immunotherapy.” Science 348(6230):69–74, 2015.[35] Gillette MA, Satpathy S, Cao S, et al. “Clinical Proteomic Tumor Analysis Consortium (CPTAC) Investigates 2800 Putative Cancer Targets.” Cell, 179(2):340–355.e11, 2019.[36] Menden MP, Iorio F, Garnett M, et al. “Machine Learning for Integrative Analysis of Cancer Drug Sensitivity.” Nat. Commun. 9: 406, 2018.[37] Li B, Chen J, Wang X, et al. “CRISPR screening identifies novel immunotherapy targets in Chinese colorectal cancer cohort.” Nature Communications, 14: 3456, 2023.[38] Xie ZY, Chen H, Song Y, et al. “China’s integration into global oncology clinical trials: trends and challenges.” Lancet Oncology, 24(2): e75–e83, 2023.[39] National Cancer Institute. “F U.S. Food and Drug Administration. “FDA Approves Sotorasib in Combination With Panitumumab for KRAS G12C–Mutated Metastatic Colorectal Cancer.” FDA News Release, May 2024. ” NCI News Release, April 2024. [40] Krishnamurthy, Savitri et al. “Fully Automated Artificial Intelligence Solution for Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Scoring in Breast Cancer: A Multireader Study.” JCO precision oncology vol. 8 (2024): e2400353.[41] https://keai-kaist-ac-kr.libproxy1.nus.edu.sg/projects/smc-digital-pathology-consortium/[42] Dong, Yunyun et al. “Multi-channel multi-task deep learning for predicting EGFR and KRAS mutations of non-small cell lung cancer on CT images.” Quantitative imaging in medicine and surgery vol. 11,6 (2021): 2354-2375.[43] Paz‐Ares L, et al. “Tarlatamab (AMG 757), a First‑in‑Class DLL3/CD3 Bispecific T‑Cell Engager, in Recurrent Small‑Cell Lung Cancer: An Open‑Label, Phase I Study.” Journal of Clinical Oncology, 41(15_suppl):8507, 2023.*封面图片来源：神笔PRO如果您认同文章中的观点、信息，或想进一步讨论，请与我们联系；也可加入动脉网行业社群，结交更多志同道合的好友。近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。文中如果涉及企业信息和数据，均由受访者向分析师提供并确认。动脉网，未来医疗服务平台

AACR会议细胞疗法免疫疗法疫苗

2025-05-23

·PRNewswire

Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting

SHANGHAI, May 23, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced multiple clinical research results to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including phase Ib/II clinical study data of 9MW2821 (Bulumtatug Fuvedotin, BFv), a novel Nectin-4 targeting ADC, in combination with Toripalimab in locally advanced or metastatic uroepithelial carcinoma to be presented as oral presentation, and clinical study data of 7MW3711 and 9MW2921, a novel B7-H3 targeting ADC and a novel Trop-2 targeting ADC respectively, to be presented as poster presentations. The study of 9MW2821 was the only selected Chinese oral presentation in the field of urothelial carcinoma at this meeting. Nectin-4 ADC (9MW2821): In the phase Ib/II clinical study of 9MW2821 in combination with Toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma (la/mUc), a total of 40 patients with previously untreated for la/mUC were enrolled in the study and were treated with 9MW2821 (1.25 mg/kg) and Toripalimab (240 mg). As of December 19, 2024, the objective response rate (ORR) was 87.5% and the confirmed ORR was 80%. The disease control rate (DCR) was 92.5%. Median progression-free survival (PFS) and duration of response (DoR) have not been achieved. No new safety signals of 9MW2821 or Toripalimab were observed in this study. 9MW2821 stands out as the first clinical-stage drug candidate among Chinese companies for this specific target. And it's the first Nectin-4 targeting ADC to disclose clinical efficacy data in cervical, esophageal, and breast cancers. Currently, 3 Phase III pivotal clinical trials are ongoing. Its monotherapy and combination therapy with Toripalimab for urothelial carcinoma have been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. It has also been granted Fast Track Designations (FTD) for 3 indications and Orphan Drug Designation (ODD) for 1 indication by the U.S. Food and Drug Administration (FDA). B7-H3 ADC (7MW3711): 7MW3711 has enrolled 43 patients as of January 2, 2025 in a phase I/II clinical study in patients with advanced solid tumors. During the dose-escalation phase, dose-limiting toxicity (DLT) was not observed and the maximum tolerated dose (MTD) has not been reached. In patients evaluated at doses of 4.5 mg/kg or higher, the ORR for esophageal cancer, ovarian cancer, and prostate cancer was 33.3%, 60.0%, and 50.0%, respectively, and the DCR was 100%. In the phase I/II clinical study in lung cancer patients, 37 lung cancer patients were enrolled as of January 8, 2025, including 16 small cell lung cancer (SCLC) patients and 21 non-small cell lung cancer (NSCLC) patients. Common grade ≥3 adverse reactions were neutrophil count decreased, white blood cell count decreased, anemia, lymphocyte count decreased, and platelet count decreased. Among the 25 patients who received 7MW3711 at a dose of 4.5 mg/kg or greater and completed at least one tumor evaluation, the ORR was 36.0% and the DCR was 96.0%; of these, the ORR and DCR were 62.5% and 100.0%, respectively, for patients with small-cell lung cancer at a dose of 4.5 mg/kg. Among squamous lung cancer (Sq-NSCLC) patients with a B7-H3 H-score >5, the ORR and DCR were 37.5% and 87.5%, respectively. The study results suggest that 7MW3711 has a tolerable safety profile and good anti-tumor activity in patients with advanced tumors such as lung, esophageal, prostate and ovarian cancers. 7MW3711 was developed with Mabwell's Interchain-Disulfide Drug Conjugate (IDDC™) platform. It consists of an innovative antibody molecule, a novel linker, and a novel payload: Mtoxin™, which is a topoisomerase I inhibitor. It has been granted ODD by the FDA for the treatment of SCLC. Trop-2 ADC (9MW2921): In the first-in-human clinical study in patients with advanced solid tumors, a total of 39 patients were enrolled as of November 12, 2024. The most common ≥3 grade adverse were stomatitis, anemia, white blood cell count decreased, neutropenia, lymphocyte count decreased, etc. The ORR of 3.0 mg/kg dose group was 42.1% and the DCR was 84.2%. Under this dose level, the ORR and DCR was 75% and 100% for endometrial cancer, 50% and 75% for HR+/HER2- breast cancer, 50% and 100% for gastric cancer, 25% and 100% for non-squamous non-small cell lung cancer. The study result suggests that 9MW2921 has a tolerable safety profile and good anti-tumor activity in patients with advanced tumors. 9MW2921 was developed with Mabwell's Interchain-Disulfide Drug Conjugate (IDDC™) platform. It consists of an innovative antibody molecule, a novel linker, and a novel payload: Mtoxin™, which is a topoisomerase I inhibitor. About Mabwell Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established. Mabwell has 16 pipeline products in different stages based on a world-class and state-of-the-art R&D engine, including 12 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 3 products have been approved and commercialized, 1 product has been filed for market approval, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for "Significant New Drugs Development", 2 projects for National Key R&D Programmes, and multiple provincial and municipal science and technological innovation projects. Mabwell's Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA, FDA and EMA, and has passed the EU QP Audit. The large-scale manufacturing base in Shanghai and the ADC commercialized manufacturing base in Taizhou are under construction. Our mission is "Explore Life, Benefit Health" and our vision is "Innovation, from ideas to reality". For more information, please visit . Forward-Looking Statements This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company's product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. "Forward-looking statements" are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would," and similar expressions and the negatives of those terms. Forward-looking statements are based on the Company's current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company's control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the potential impact of COVID-19; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results. The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement. SOURCE Mabwell WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

快速通道ASCO会议临床结果孤儿药突破性疗法

2025-05-23

·PRNewswire

Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025

ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), achieved an overall response rate (ORR) of 36.4% and disease control rate (DCR) of 100% in checkpoint inhibitor (CPI)-resistant melanoma patients in the ongoing STAMINA-01 trial, with one patient maintaining a partial response (PR) and remained on treatment for over 2 years without any safety concerns. In CPI-resistant non-small cell lung cancer (NSCLC), the combination of ATG-037 and pembrolizumab achieved an ORR of 22% and DCR of 67% in the same study. ATG-008, an oral dual mTORC1/2 inhibitor, in combination with toripalimab, achieved an ORR of 22.2% and DCR of 85.2% in CPI-resistant cervical cancer patients in the ongoing TORCH-2 trial. SHANGHAI and HONG KONG, May 22, 2025 /PRNewswire/ -- Antengene Corporation Limited (" Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that it will present the latest clinical data of its CD73 oral small molecule inhibitor ATG-037 and oral dual mTORC1/2 inhibitor ATG-008 in Poster Presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30th to June 3rd in Chicago, IL, the United States. Details of the Poster Presentations: ATG-037 (CD73 Small Molecule Inhibitor) Title: A First-In-Human Phase I/Ib study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Advanced Solid Tumors - STAMINA-01 Abstract: 3123 Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Date: June 2, 2025 Time: 1:30 PM - 4:30 PM (Central Time) 2:30 AM - 5:30 AM, June 3, 2025 (Beijing Time) Robust clinical benefit observed in CPI-resistant patients: As of April 27, 2025, the study has already completed the dose escalation part in which 43 patients were enrolled and received monotherapy. Among them, 28 CPI-resistant patients also received the combination therapy. Among patients treated with the combination therapy, 6 patients (4 melanoma and 2 NSCLC patients) achieved a confirmed PR with an ORR of 21.4%, and 16 patients achieved stable disease (SD) with a DCR of 78.6%. The combination regimen delivered particularly encouraging efficacy in melanoma, with all 11 CPI-resistant patients achieving disease control (DCR 100%) and an ORR of 36.4% (4 PRs), including 1 patient having maintained PR and remained in the study for over 2 years without any safety concerns. In CPI-resistant NSCLC, the combination regimen achieved an ORR of 22% (PRs) and a DCR of 67%. These results highlight the potential of ATG-037 to deliver meaningful clinical benefit across multiple tumor types, reinforcing its promise as a novel treatment option in CPI-resistant cancers. Manageable safety profile: Treatment-related adverse events were reported in 56% (24/43) of patients receiving monotherapy and 61% (17/28) of patients receiving the combination therapy. The majority of these TRAEs were grade 1-2. Only one serious TRAE (grade 3 immune mediated hepatitis) was observed in the study. Two key differentiators: ATG-037 is an oral small molecule CD73 inhibitor offering greater convenience over intravenous (IV) injectable agents and is uniquely designed to overcome the 'hook effect' commonly seen in anti-CD73 antibodies, enabling complete and more effective CD73 inhibition. The STAMINA-01 trial: STAMINA-01 is a Phase I/Ib study jointly conducted by Antengene and MSD (Merck & Co., Inc., Rahway, NJ, USA). The study was designed to evaluate the safety, pharmacokinetics, and optimal dosing of ATG-037 as a monotherapy and in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with refractory/relapsed solid tumors. At present, dose optimization and dose expansion parts of the study are being carried out as planned in China and Australia. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. ATG-008 (mTORC1/2 Small Molecule Inhibitor) Title: A TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced cervical cancers with prior anti-PD-(L)1 therapy Abstract: 5540 Session: Gynecologic Cancer Date: June 1, 2025 Time: 9:00 AM - 12:00 PM (Central Time) 10:00 PM, June 1, 2025 - 1:00 AM, June 2, 2025 (Beijing Time) The TORCH-2 trial: ATG-008 is an oral dual mTOR1/2 inhibitor. The TORCH-2 trial is a Phase I/II dose escalation and dose expansion study of ATG-008 in combination with the anti-PD-1 monoclonal antibody toripalimab in patients with advanced solid tumors. This abstract reports data from patients with advanced cervical cancer who had previously received at least prior 1 line of anti-PD-(L)1 therapy and 1 line of platinum chemotherapy, regardless of the PD-L1 expression. As of November 25, 2024, 30 qualified patients were enrolled and received ATG-008 15 mg orally once a day (QD) in combination with toripalimab 240 mg, once every 21 days (Q3W). Among them, 14 and 16 patients had received 1 and at least 2 prior lines of systemic therapy, respectively. The median time since initial diagnosis was 37 months. Encouraging efficacy in patients with CPI-resistant cervical cancer: Among 27 efficacy-evaluable patients, the combination regimen achieved an ORR of 22.2% and a DCR of 85.2%. The ORRs of PD-L1 positive and PD-L1 negative populations were 30% (3/10) and 33.3% (2/6), respectively. The median time to response was 1.7 months (1.4, 4.2) and the median duration of response (DOR) was 5.7 months (95% CI: 2.7, NE). The median progression-free survival (PFS) was 4.2 months (95% CI: 3.3, 5.8) and the median overall survival (OS) was 21.4 months (95% CI: 15.5, NE). These results underscore the potential of ATG-008 in combination with toripalimab in providing meaningful clinical benefit for CPI-resistant cervical cancer patients, reinforcing its promise as a novel treatment option for this difficult-to-treat patient population. Manageable safety profile: All 30 patients experienced at least one TEAE, and 22 patients (73.3%) reported grade ≥3 TRAEs. The most common all-grade TRAEs were hyperglycaemia (56.7%), rash (43.3%) and white blood cell decreased (43.3%). Most TRAEs were grade 1-2, and no TEAE led to death. About Antengene Antengene Corporation Limited ( "Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald Lung E-mail: [email protected] Mobile: +86 18420672158 PR Contacts: Peter Qian E-mail: [email protected] Mobile: +86 13062747000 SOURCE Antengene Corporation Limited WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果ASCO会议申请上市临床3期上市批准

100 项与特瑞普利单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC	DB15043

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
转移性黑色素瘤	中国	上海君实生物医药科技股份有限公司	2025-04-22
不可切除的黑色素瘤	中国	上海君实生物医药科技股份有限公司	2025-04-22
晚期肝细胞癌	中国	上海君实生物医药科技股份有限公司	2025-03-18
转移性食管鳞状细胞癌	欧盟	-	2024-09-19
转移性食管鳞状细胞癌	冰岛	-	2024-09-19
转移性食管鳞状细胞癌	列支敦士登	-	2024-09-19
转移性食管鳞状细胞癌	挪威	-	2024-09-19
鼻咽肿瘤	欧盟	-	2024-09-19
鼻咽肿瘤	冰岛	-	2024-09-19
鼻咽肿瘤	列支敦士登	-	2024-09-19
鼻咽肿瘤	挪威	-	2024-09-19
复发性食管鳞状细胞癌	欧盟	-	2024-09-19
复发性食管鳞状细胞癌	冰岛	-	2024-09-19
复发性食管鳞状细胞癌	列支敦士登	-	2024-09-19
复发性食管鳞状细胞癌	挪威	-	2024-09-19
不能切除的食管鳞状细胞癌	欧盟	-	2024-09-19
不能切除的食管鳞状细胞癌	冰岛	-	2024-09-19
不能切除的食管鳞状细胞癌	列支敦士登	-	2024-09-19
不能切除的食管鳞状细胞癌	挪威	-	2024-09-19
三阴性乳腺癌	中国	上海君实生物医药科技股份有限公司	2024-06-18

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	申请上市	加拿大	Apotex, Inc.	2024-12-01
复发性鼻咽癌	申请上市	欧盟	Tmc Pharma (Eu Ltd.	2022-11-14
复发性非鳞状非小细胞肺癌	临床3期	中国	上海君实生物医药科技股份有限公司	2024-07-11
难治性经典霍奇金淋巴瘤	临床3期	中国	上海君实生物医药科技股份有限公司	2023-12-28
局限期小细胞肺癌	临床3期	美国	上海君实生物医药科技股份有限公司	2023-11-15
局限期小细胞肺癌	临床3期	中国	上海君实生物医药科技股份有限公司	2023-11-15
局限期小细胞肺癌	临床3期	比利时	上海君实生物医药科技股份有限公司	2023-11-15
局限期小细胞肺癌	临床3期	法国	上海君实生物医药科技股份有限公司	2023-11-15
局限期小细胞肺癌	临床3期	格鲁吉亚	上海君实生物医药科技股份有限公司	2023-11-15
局限期小细胞肺癌	临床3期	德国	上海君实生物医药科技股份有限公司	2023-11-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05635643 (AACR2025 \| PipelineReview) 人工标引	临床1期	晚期恶性实体瘤	30	CHS-114 (solid tumors + Arm 1a: CHS-114 dose escalation from 5 to 1200 mg)	襯壓齋鏇蓋築齋廠顧製(夢鬱選範網簾憲窪淵憲) = None 選繭窪鑰鹹顧蓋齋窪糧 (繭製鏇繭築簾觸蓋醖鏇 ) 更多	积极	2025-04-28
				CHS-114 (HNSCC + Arm 1b: 2 dose levels [DL1 or DL2] of pharmacologically active CHS-114)
NCT04844385 (GASTO 1071, Literature) 人工标引	临床2期	局部晚期食管鳞状细胞癌新辅助	124	Neoadjuvant toripalimab plus chemotherapy followed by CCRT (60Gy)	餘蓋糧顧衊夢簾餘觸糧(簾簾選網壓憲積壓糧鏇) = 網選鹹鏇觸繭簾齋網衊糧構鹽簾鹽壓顧積憲選 (壓齋醖鬱觸築餘窪襯廠, 53.9 ~ 78.3) 更多	积极	2025-04-03
				Neoadjuvant toripalimab plus chemotherapy followed by CCRT (50Gy)	餘蓋糧顧衊夢簾餘觸糧(簾簾選網壓憲積壓糧鏇) = 繭膚網積簾觸齋襯蓋夢糧構鹽簾鹽壓顧積憲選 (壓齋醖鬱觸築餘窪襯廠, 53.7 ~ 78.8) 更多
NCT04475016 (Pubmed \| Cancer Cell) 人工标引	临床2期	阴茎鳞状细胞癌新辅助	29	Toripalimab + Nimotuzumab + Taxol-based chemotherapy	獵鑰膚選獵齋憲鑰夢夢(齋鏇範衊觸鬱鹹艱蓋壓) = 醖襯醖壓壓構觸膚壓顧蓋夢鏇壓遞構鏇艱糧鏇 (齋網蓋夢壓範壓醖餘積, 29.4 ~ 67.5) 更多	积极	2025-04-01
ESMO_ELCC2025	N/A	非小细胞肺癌 III期	-	Toripalimab plus chemotherapy	齋獵餘夢遞淵鬱製鏇構(構膚糧顧齋襯獵衊築築) = No other grade 3-5 TRAEs were further reported 願選膚構鑰廠積夢積鏇 (鹹製鬱範鬱鏇獵繭願鹽 ) 更多	-	2025-03-26
				Adjuvant toripalimab
NEWS 人工标引	临床阶段不明	肾细胞癌新辅助	21	特瑞普利单抗+阿昔替尼 (手术)	繭膚壓夢觸網淵顧醖願(選願鏇構蓋糧膚願鏇襯) = 鑰膚製廠衊齋餘鹽壓艱齋鏇願醖夢餘衊積衊願 (窪憲積淵觸窪衊餘鏇願 ) 更多	积极	2025-03-25
				手术	繭膚壓夢觸網淵顧醖願(選願鏇構蓋糧膚願鏇襯) = 築獵願醖鹹廠鹹糧鬱衊齋鏇願醖夢餘衊積衊願 (窪憲積淵觸窪衊餘鏇願 ) 更多
ESMO_SRC2025	临床2期	胸腺上皮肿瘤一线 \| 维持	24	Toripalimab + Paclitaxel + Carboplatin	鹽鹹觸壓壓蓋製壓齋蓋(鏇範襯廠製製鏇蓋獵憲) = 鏇廠製願顧襯鹹衊遞鬱範鏇簾鏇鏇憲艱夢廠築 (願艱積窪廠選廠網鬱簾, 14.0 ~ 32.0) 更多	积极	2025-03-21
ASCO_GU2025 人工标引	N/A	HER2阳性肌层浸润性膀胱癌新辅助 HER2 Positive	28	Toripalimab + Disitamab vedotin	積遞襯廠選憲簾衊構範(艱範艱獵鹽膚繭簾繭鬱) = 顧鏇淵願夢壓範糧製齋簾廠窪窪艱積衊鏇鹽積 (鹹艱構蓋窪餘繭獵網築 ) 更多	积极	2025-02-13
NCT05297552 (RC48-C017, ASCO_GU2025) 人工标引	临床2期	HER2阳性肌层浸润性膀胱癌辅助 \| 新辅助 HER2 Expression	47	Disitamab vedotin+toripalimab	鑰憲齋淵構衊鬱願膚廠(鑰選窪獵廠鹽醖夢網艱) = 觸鹹蓋築夢構選鬱鹽蓋憲襯構憲鑰廠醖構蓋夢 (憲醖壓觸顧淵鏇醖積顧, 45.1 ~ 79.6) 更多	积极	2025-02-13
				Disitamab vedotin+toripalimab (PD-L1-positive)	鑰憲齋淵構衊鬱願膚廠(鑰選窪獵廠鹽醖夢網艱) = 膚淵構選獵蓋壓構積鏇憲襯構憲鑰廠醖構蓋夢 (憲醖壓觸顧淵鏇醖積顧 )
NCT05024812 (ASCO_GI2025) 人工标引	临床1/2期	胃腺癌 \| 胃食管交界处腺癌一线 PD-L1 Negative \| PD-L1 Low Expression	30	Fruquintinib + toripalimab + oxaliplatin + S-1	廠襯齋衊壓憲鹽製鏇壓(鬱壓顧齋簾築夢鬱淵蓋) = 構艱窪遞鹽獵餘觸膚襯衊膚衊構醖壓淵壓顧築 (鑰觸製網製築廠觸餘壓, 5.68 ~ NA) 更多	积极	2025-01-23
				Fruquintinib + toripalimab + oxaliplatin + S-1 (Pts with CPS < 5)	鹽膚壓衊繭鏇齋簾糧鹽(網鹽願餘膚範鏇蓋願襯) = 糧艱鑰鑰蓋鹹顧鏇鑰餘鬱壓淵築築糧積糧壓壓 (膚構獵選築醖網餘鹽窪 )
NCT04144608 (Pubmed \| Med) 人工标引	临床2期	非小细胞肺癌	29	Toripalimab + Platinum-doublet chemotherapy	齋構網築鹽齋糧製餘簾(齋觸鑰積構餘網夢構選) = 壓積鹽鹽夢鏇艱鏇構窪壓鹽襯糧顧糧衊艱獵鏇 (窪襯網積蓋鏇範齋壓鬱 ) 更多	积极	2025-01-01